secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001628280-25-012335
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys prices $175M public offering (12.96M shares at $13.50); net proceeds ~$164.2M
--------------------------------------------------------------------------------

- Offering of 12,962,962 shares at $13.50; gross proceeds $175M; net proceeds ~$164.2M.
- Underwriters have 30-day option for additional 1,944,444 shares, adding up to $26.3M.
- Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.
- Joint book-runners: BofA Securities, Evercore ISI, Goldman Sachs, Stifel, Wells Fargo.
- Expected to close March 13, 2025; subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000162828025012335/0001628280-25-012335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000162828025012335/mlys-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-012335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer